Novo Nordisk announced that semaglutide, the active ingredient in the injectable weight-loss drug Wegovy, will become available as a daily oral tablet in the UK. The pharmaceutical company says the pill form offers a more convenient alternative to the current once-weekly injection that patients self-administer.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. These drugs work by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar levels. The injectable version of Wegovy has become increasingly popular for weight management, particularly after celebrities and influencers highlighted their experiences with the medication.
The tablet formulation addresses a practical barrier for some patients. Weekly injections require storage considerations, proper injection technique, and the psychological challenge some people face with needles. A daily pill removes these obstacles for individuals who prefer oral medications or struggle with injection anxiety.
Novo Nordisk has not yet disclosed specific timelines for UK availability or pricing details for the tablet form. The company did not provide information about dosing equivalency between the injection and pill versions, though pharmaceutical research typically ensures oral formulations deliver comparable therapeutic effects to their injectable counterparts.
The shift toward oral administration reflects a broader trend in pharmaceutical development. As GLP-1 medications gain mainstream attention for weight management, manufacturers recognize that accessibility shapes treatment adherence. Patients more likely to take medication consistently achieve better outcomes than those who struggle with their prescribed regimen.
This development comes as demand for semaglutide continues to rise globally. Supply chain challenges have affected availability in various markets, and expanding the product line to include pills could help Novo Nordisk meet growing patient demand while serving different consumer preferences.
For UK patients currently using Wegovy injections or considering the medication, the pill option will provide flexibility in how they administer treatment. Healthcare providers will need